Aptose Reports Results for the Third Quarter 2024
08. November 2024 16:01 ET
|
Aptose Biosciences, Inc.
SAN DIEGO and TORONTO, Nov. 08, 2024 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly...
Aptose Announces Results from Special Meeting of Shareholders
05. September 2024 16:15 ET
|
Aptose Biosciences, Inc.
Aptose Announces Results from Special Meeting of Shareholders
Aptose Receives $10 Million Through a Facility Agreement with Hanmi; Negotiating Future Collaboration Agreement with Hanmi to Jointly Develop Tuspetinib
30. August 2024 16:30 ET
|
Aptose Biosciences, Inc.
Aptose Receives $10 Million Through a Facility Agreement with Hanmi;
Negotiating Future Collaboration Agreement with Hanmi to Jointly Develop Tuspetinib
Aptose Announces Adjournment of its Special Meeting of Shareholders
15. August 2024 16:30 ET
|
Aptose Biosciences, Inc.
Aptose Announces Adjournment of its Special Meeting of Shareholders
Aptose Reports Results for the Second Quarter 2024
08. August 2024 17:06 ET
|
Aptose Biosciences, Inc.
Aptose Reports Results for the Second Quarter 2024
Aptose Announces Receipt of Deficiency Notice from Nasdaq
19. Juli 2024 17:00 ET
|
Aptose Biosciences, Inc.
SAN DIEGO and TORONTO, July 19, 2024 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly...
Aptose Announces Results from Annual and Special Meeting of Shareholders
18. Juni 2024 17:30 ET
|
Aptose Biosciences, Inc.
Aptose Announces Results from Annual and Special Meeting of Shareholders
Aptose Presents Tuspetinib (TUS) Clinical and Preclinical Findings at European Hematology Association (EHA) 2024 Hybrid Congress
14. Juni 2024 07:30 ET
|
Aptose Biosciences, Inc.
Aptose Presents Tuspetinib (TUS) Clinical and Preclinical Findings at European Hematology Association (EHA) 2024 Hybrid Congress
Aptose Announces Closing of $4.43 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
03. Juni 2024 16:30 ET
|
Aptose Biosciences, Inc.
Aptose Announces Closing of $4.43 Million Registered Direct Offering Priced At-the-Market
Under Nasdaq Rules
Aptose Announces $4.43 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
31. Mai 2024 08:00 ET
|
Aptose Biosciences, Inc.
Aptose Announces $4.43 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules